THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [3.24] ID: TIP-MED-000024 ⚠️ HIGH-ALERT / SPECIALIST SUPERVISION

Rivaroxaban

Active Ingredient / Scientific Identity: Rivaroxaban • Class: Direct Oral Anticoagulant (DOAC); Selective Direct Factor Xa Inhibitor

⚖️ Compare Profile
THE INDIAN PHARMACIST — Educational Reference Sheet
Profile: Rivaroxaban ([3.24] | ID: TIP-MED-000024) • Last Reviewed: 2026-11-10
Source URL: https://theindianpharmacist.com/medicine/3-24-rivaroxaban/
Generic / Entity NameRivaroxaban ([3.24])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassDirect Oral Anticoagulant (DOAC); Selective Direct Factor Xa Inhibitor
Available Dosage FormsOral Film-Coated Tablets: 2.5 mg, 10 mg, 15 mg, 20 mg
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: Calculate CrCl via Cockcroft-Gault (actual body weight, NOT normalised eGFR). NVAF: CrCl >50 mL/min: 20 mg OD with mea
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o🚨 Clinically High-Alert: Independent Dose & Route Verification Required

1. Clinical & Scientific Overview

Rivaroxaban (TIP-MED-000024, Reference Code [3.24]) is classified under Cardiovascular & Antithrombotic Medicines (Ch 03) as a Direct Oral Anticoagulant (DOAC); Selective Direct Factor Xa Inhibitor. Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 03 [3.24], p. 32): Xarelto (Bayer), Rivaban (Lupin), Xabator (Torrent), Rivarox (Zydus), Cerdak — Strengths & Dosage Forms: Oral Film-Coated Tablets: 2.5 mg, 10 mg, 15 mg, 20 mg
Representative Indian Market Examples (Edition 2.7 Ch 03 [3.24], p. 32): Xarelto (Bayer), Rivaban (Lupin), Xabator (Torrent), Rivarox (Zydus), Cerdak — Strengths & Dosage Forms: Oral Film-Coated Tablets: 2.5 mg, 10 mg, 15 mg, 20 mg
Dosage Forms & Available Strengths:
Oral Film-Coated Tablets: 2.5 mg, 10 mg, 15 mg, 20 mg
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Direct Oral Anticoagulant (DOAC); Selective Direct Factor Xa Inhibitor acting on target receptor/enzyme pathways in Cardiovascular & Antithrombotic Medicines (Ch 03): clinical efficacy is mediated via Direct Oral Anticoagulant (DOAC); Selective Direct Factor Xa Inhibitor for Non-valvular atrial fibrillation (20 mg OD, or 15 mg OD in moderate CKD); treatment of acute DVT/PE (15 mg BD x 21 days, then 20 mg OD); extended VTE prophylaxis (10 mg OD); atherothrombotic prevention in stable CAD or PAD (vascular dose 2.5 mg BD + aspirin 75–100 mg OD)..

4. Therapeutic Indications & Evidence-Supported Uses

  • Non-valvular atrial fibrillation (20 mg OD, or 15 mg OD in moderate CKD)
  • treatment of acute DVT/PE (15 mg BD x 21 days, then 20 mg OD)
  • extended VTE prophylaxis (10 mg OD)
  • atherothrombotic prevention in stable CAD or PAD (vascular dose 2
  • 5 mg BD + aspirin 75–100 mg OD)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: NVAF Stroke Prevention: 5 mg PO BD; reduce to 2.5 mg PO BD ONLY if >=2 of 3 'ABC' criteria are met: (A) Age >=80 years, (B) Body weight <=60 kg, (C) Serum Creatinine >=1.5 mg/dL (or CrCl 15–29 mL/min). DVT/PE Treatment: 10 mg BD for 7 days, then 5 mg BD.

Administration & Meal Timing: 15 mg and 20 mg tablets MUST be taken WITH EVENING MEAL/FOOD (increases bioavailability from 66% to >80%; taking on an empty stomach causes sub-therapeutic anticoagulation and stroke/clot risk). 2.5 mg and 10 mg tablets may be taken with or without food. | 20 mg / 15 mg OD: Once daily with the evening meal (dinner). 15 mg BD (acute DVT phase) or 2.5 mg BD: With breakfast and dinner.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: Calculate CrCl via Cockcroft-Gault (actual body weight, NOT normalised eGFR). NVAF: CrCl >50 mL/min: 20 mg OD with meal; CrCl 15–50 mL/min: 15 mg OD with meal; CrCl <15 mL/min: Avoid. Hepatic: Contraindicated in Child-Pugh B and C cirrhosis or any hepatic disease associated with coagulopathy.
Elimination & Renal Adjustment:
Renal: Calculate CrCl via Cockcroft-Gault (actual body weight, NOT normalised eGFR). NVAF: CrCl >50 mL/min: 20 mg OD with meal; CrCl 15–50 mL/min: 15 mg OD with meal; CrCl <15 mL/min: Avoid. Hepatic: Contraindicated in Child-Pugh B and C cirrhosis or any hepatic disease associated with coagulopathy.
Hepatic Impairment Considerations:
Renal: Calculate CrCl via Cockcroft-Gault (actual body weight, NOT normalised eGFR). NVAF: CrCl >50 mL/min: 20 mg OD with meal; CrCl 15–50 mL/min: 15 mg OD with meal; CrCl <15 mL/min: Avoid. Hepatic: Contraindicated in Child-Pugh B and C cirrhosis or any hepatic disease associated with coagulopathy.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Contraindicated in mechanical prosthetic heart valves, moderate-to-severe rheumatic mitral stenosis, active bleeding, pregnancy, lactation, and Child-Pugh B or C hepatic cirrhosis.

Key Clinical Precautions: Renal: Calculate CrCl via Cockcroft-Gault (actual body weight, NOT normalised eGFR). NVAF: CrCl >50 mL/min: 20 mg OD with meal; CrCl 15–50 mL/min: 15 mg OD with meal; CrCl <15 mL/min: Avoid. Hepatic: Contraindicated in Child-Pugh B and C cirrhosis or any hepatic disease associated with coagulopathy.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Epistaxis, gingival bleeding, bruising, gastrointestinal bleed, menorrhagia, dizziness.
  • Major gastrointestinal haemorrhage (slightly higher GI bleed rate than apixaban), intracranial haemorrhage, retroperitoneal bleed, spinal haematoma.
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Strong dual CYP3A4 + P-gp inhibitors (ketoconazole, itraconazole, voriconazole, ritonavir) increase rivaroxaban AUC 2
  • 5-fold (avoid combination)
  • Strong CYP3A4/P-gp inducers (rifampicin, phenytoin, carbamazepine) reduce exposure by 50% (avoid)
  • Clarithromycin/erythromycin in CKD patients increases bleeding risk
  • Additive bleeding with antiplatelets and NSAIDs

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: Verify two critical facts with every patient: (1) Are you taking the 15 mg or 20 mg tablet right in the middle of or immediately after a full dinner? Never take it with just tea or on an empty stomach. (2) If prescribed 15 mg twice daily for a fresh leg clot (DVT), confirm the exact date (Day 22) when it must be reduced to 20 mg once daily.
  • Meal & Clock Timing Instruction: 15 mg and 20 mg tablets MUST be taken WITH EVENING MEAL/FOOD (increases bioavailability from 66% to >80%; taking on an empty stomach causes sub-therapeutic anticoagulation and stroke/clot risk). 2.5 mg and 10 mg tablets may be taken with or without food. (20 mg / 15 mg OD: Once daily with the evening meal (dinner). 15 mg BD (acute DVT phase) or 2.5 mg BD: With breakfast and dinner.)
  • Missed Dose Protocol: For 15 mg or 20 mg once-daily regimen: take immediately with food on the same day as soon as remembered; if discovered the next day, skip and take only that day's tablet (never take two 20 mg tablets on the same day). For initial 15 mg BD DVT phase: take immediately to ensure 30 mg daily intake (two 15 mg tablets may be taken together once if needed during the first 21 days).
  • Geriatric Dispensing Pearl: Calculate actual Cockcroft-Gault CrCl (using age and weight, not just lab eGFR) in every elderly CGHS patient on Xarelto/Rivaroxaban—patients >75 years weighing <60 kg frequently have CrCl <50 mL/min and require the 15 mg OD renal dose.

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Film-Coated Tablets: 2.5 mg, 10 mg, 15 mg, 20 mg

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 03 [3.24] (p. 32)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

← Back to All 644 Reference Profiles 📖 Explore 40 Knowledge Hub Articles → ✉️ Report Errata / Feedback
Educational Reference Notice: This printout from THE INDIAN PHARMACIST (https://theindianpharmacist.com/medicine/3-24-rivaroxaban/, Last Reviewed: 2026-11-10) is an educational reference sheet for students and healthcare learners. It is NOT an official prescribing guideline or patient-specific treatment order.